- Home
- FIGS vs IMNM Comparison
FIGS vs IMNM Comparison
Compare FIGS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIGS | IMNM |
|---|---|---|
| Founded | 2013 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | FIGS | IMNM |
|---|---|---|
| Price | $12.23 | $22.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $9.20 | ★ $31.44 |
| AVG Volume (30 Days) | ★ 2.8M | 2.7M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 91.65 | N/A |
| EPS | ★ 0.11 | N/A |
| Revenue | ★ $581,034,000.00 | $9,679,000.00 |
| Revenue This Year | $9.08 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $115.25 | ★ N/A |
| Revenue Growth | ★ 5.90 | N/A |
| 52 Week Low | $3.57 | $5.15 |
| 52 Week High | $12.21 | $25.30 |
Technical Indicators
Market Signals| Indicator | FIGS | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 73.87 | 60.82 |
| Support Level | $11.34 | $19.37 |
| Resistance Level | $12.20 | $25.30 |
| Average True Range (ATR) | 0.44 | 1.61 |
| MACD | -0.02 | 0.07 |
| Stochastic Oscillator | 93.71 | 61.31 |
Price Performance
Historical ComparisonAbout FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company generates maximum revenue from United States. Sales are generated through the Company's digital platforms.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.